PITTSBURGH, PA – Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab (Tecentriq®) plus modified FOLFOX6 and bevacizumab (Avastin®) compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology. The combination also produced higher response rates and substantially reduced primary disease progression.

Approximately 5% of patients with metastatic colorectal cancer have tumors characterized by dMMR or MSI-H, a molecular subtype that is often responsive to immunotherapy. Although immune checkpoint inhibitors have transformed the treatment of dMMR/MSI-H metastatic colorectal cancer, approximately one-third of patients experience primary resistance or early disease progression with single agent immunotherapy. COMMIT was designed to determine whether adding chemotherapy and bevacizumab could improve outcomes.

The COMMIT trial enrolled patients with previously untreated dMMR/MSI-H metastatic colorectal cancer and compared atezolizumab alone with atezolizumab combined with modified FOLFOX6 chemotherapy and bevacizumab. Patients receiving the combination experienced:

58% reduction in the risk of progression or death (HR 0.42)

Median progression-free survival of 24.5 months versus 5.3 months

Objective response rate of 86% versus 46%

Complete responses in 36% versus 19%

Marked reduction in primary disease progression.

“These findings demonstrate that combining chemotherapy and bevacizumab with immunotherapy may provide a meaningful clinical benefit for patients with dMMR/MSI-H metastatic colorectal cancer,” said Caio Max Sao Pedro Rocha Lima, MD of Wake Forest University School of Medicine, and Principal Investigator of the COMMIT trial. “The study showed not only longer progression-free survival, but also a dramatic reduction in the number of patients whose disease progressed as their best response to treatment. These results may help inform future treatment strategies for this patient population.”

“Clinical trials like COMMIT are essential to advancing treatment for patients with colorectal cancer,” added Co-Principal investigator, Michael Overman, MD of The University of Texas MD Anderson Cancer Center. “The study provides evidence supporting a combination approach in the first-line setting and underscores the importance of continued collaboration to identify therapies that offer the greatest benefit for patients.”

The COMMIT trial (NRG-GI004/SWOG S1610; NCT02997228) was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and led by the NCI-funded NRG Oncology in collaboration with SWOG with participation from the NCI-funded national clinical trials network (NCTN) as part of a collaboration with Genentech, a member of the Roche Group, and the NCI through a Cooperative Research and Development Agreement (CRADA). Support by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180868 (NRG Oncology Operations) and U10CA180822 (NRG Oncology SDMC) from the National Cancer Institute (NCI), with additional support from Genentech, a member of the Roche Group.

Citation:

Caio Max Sao Pedro Rocha Lima et al. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. J Clin Oncol 0, JCO-25-03052 DOI:10.1200/JCO-25-03052

Notes

Tecentriq^® (atezolizumab) and Avastin^® (bevacizumab) are registered trademarks of Genentech, a member of the Roche Group.

About NRG Oncology
NRG Oncology conducts practice-changing, multi-institutional clinical and translational research to improve the lives of patients with cancer. Founded in 2012, NRG Oncology is a Pennsylvania-based nonprofit corporation that integrates the research of the legacy National Surgical Adjuvant Breast and Bowel Project (NSABP), Radiation Therapy Oncology Group (RTOG), and Gynecologic Oncology Group (GOG) programs. The research network seeks to carry out clinical trials with emphases on gender-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology’s extensive research organization comprises multidisciplinary investigators, including medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians, and encompasses more than 1,300 research sites located world-wide with predominance in the United States and Canada. NRG Oncology is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI’s National Clinical Trials Network. www.nrgoncology.org

###

Journal

Journal of Clinical Oncology

Funder

NIH/National Cancer Institute

DOI

10.1200/JCO-25-03052

Hepatocellular carcinoma is the most common type of primary liver cancer and is often diagnosed at an advanced stage. One particularly challenging subgroup comprises patients whose tumors infiltrate major branches of the portal vein, drastically reducing survival prospects and complicating treatment protocols. Traditional systemic therapies have yielded modest benefits, and locoregional approaches often fail to achieve durable control. Against this backdrop, the DurHope study explores a dual-modality approach with the immune checkpoint inhibitor durvalumab, administered alongside HAIC-FOLFOX, followed by maintenance immunotherapy to sustain anti-tumor effects.

Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody designed to unleash the patient’s own immune system against cancer cells. The HAIC-FOLFOX regimen involves delivering chemotherapy agents directly through the hepatic artery to maximize local cytotoxic action while minimizing systemic toxicity. By combining these modalities, the study aims to exploit synergistic mechanisms: HAIC-FOLFOX mediates direct tumor cell kill and antigen release, potentially enhancing the immune response that durvalumab seeks to amplify.

The DurHope study enrolled patients with unresectable hepatocellular carcinoma exhibiting major portal vein invasion. The therapeutic sequence commenced with durvalumab administration concurrent with the HAIC-FOLFOX cycle, followed by maintenance durvalumab monotherapy to perpetuate immune activation. This strategy was carefully designed to balance aggressive tumor cytoreduction with controlled immune modulation, targeting both cancer cell eradication and prevention of relapse.

Clinical outcomes from the trial demonstrated impressive tumor response rates, including partial and complete responses, as assessed by radiological criteria. Importantly, median progression-free survival was extended beyond historical controls treated with systemic therapy alone. This enhancement in disease control translated into prolonged overall survival, marking a significant improvement for a subgroup typically characterized by rapid disease progression and low survival rates.

Mechanistic analyses shed light on the immunobiological landscape underpinning treatment effects. HAIC-FOLFOX was found to induce immunogenic cell death, releasing neoantigens that facilitated dendritic cell activation and subsequent priming of cytotoxic T lymphocytes. Durvalumab’s role in blocking PD-L1 thereby prevented cancer cells from evading immune detection, permitting sustained immune-mediated tumor eradication. This dual-mode engagement of cytotoxic chemotherapy and immunotherapy exemplifies a forward-looking paradigm in oncology.

Safety profiles observed in the DurHope study were consistent with expectations from both therapeutic components. Adverse events were predominantly manageable and aligned with known toxicities of durvalumab and FOLFOX chemotherapy. Close monitoring for immune-related adverse events during maintenance therapy ensured prompt intervention, maintaining patient safety while delivering potent oncologic benefit.

One of the study’s intriguing findings was the quality and durability of responses in patients with extensive portal vein involvement. Traditional therapies often result in disease stabilization rather than regression in this population, but the combination employed in DurHope facilitated notable tumor burden reduction. This result prompts reconsideration of therapeutic nihilism in advanced HCC cases, suggesting that aggressive, yet targeted, multimodal therapy can alter the natural disease course.

These clinical advancements were complemented by biomarker analyses aimed at refining patient selection. Preliminary data indicated that baseline PD-L1 expression and certain immune cell infiltration patterns within tumor microenvironments correlated with enhanced treatment responsiveness. This insight opens avenues for personalized therapy protocols, where immunogenomic profiling could optimize therapeutic outcomes by identifying patients most likely to benefit.

Apart from clinical efficacy, the integration of HAIC-FOLFOX with immune checkpoint blockade introduces a practical model for multidisciplinary cancer care. The hepatic artery infusion demands interventional radiology expertise, while immunotherapy requires oncological vigilance and immune monitoring. Consequently, the success of this approach underscores the value of coordinated, specialized care pathways in managing complex malignancies.

The DurHope study also contributes to the evolving discourse on the role of maintenance immunotherapy in solid tumors. While immune checkpoint inhibitors have transformed treatment landscapes, strategies for sustained immune engagement remain under exploration. Here, the ongoing durvalumab maintenance phase demonstrated feasibility and efficacy, highlighting the importance of extended immunomodulation in preventing relapse and consolidating initial tumor responses.

Looking forward, the favorable findings from this phase 2 investigation warrant further validation in larger, randomized phase 3 trials. Such studies could confirm durability of responses, evaluate long-term survival benefits, and expand understanding of resistance mechanisms. Additionally, exploration of combinations with other immunotherapeutic agents or incorporation of novel biomarkers could further optimize therapeutic efficacy and minimize toxicity.

This pioneering research also raises intriguing biological questions about tumor-immune system dynamics in the context of locoregional chemotherapy. Delineating how chemotherapy-induced tumor cell death influences immune priming and checkpoint blockade responsiveness will be key to refining this therapeutic axis. Insights gleaned may translate into enhanced regimens not only for HCC but for other solid tumors characterized by immune evasion.

In conclusion, the DurHope study presents a compelling case for durvalumab combined with HAIC-FOLFOX, followed by maintenance durvalumab, as a potent treatment strategy for hepatocellular carcinoma with major portal invasion. This approach integrates cytotoxic chemotherapy with immune checkpoint inhibition to deliver superior clinical outcomes and challenges prevailing treatment paradigms. As liver cancer continues to pose a formidable global health challenge, innovations like these offer renewed hope for patients facing the dire prognosis of advanced disease stages.

The field of oncology stands at an inflection point where immune-oncology coupled with precision locoregional therapies promises to reshape standards of care. The DurHope study exemplifies this shift by harnessing the complementary strengths of immunotherapy and targeted chemotherapy infusion. Such investigations herald a future where previously intractable cancers become manageable, or even curable, through intelligent, multi-modal therapeutic strategies.

This remarkable progress reinforces the critical importance of continued collaborative research and clinical innovation within hepatology and oncology communities globally. It also emphasizes the need for developing infrastructure and expertise to implement complex treatment regimens that can deliver maximal benefit while maintaining safety. Ultimately, the DurHope study introduces a beacon of optimism that sophisticated immune-chemotherapy combinations may dramatically improve survival and quality of life for patients afflicted by one of the deadliest liver cancers.

Subject of Research:
Durvalumab combined with hepatic artery infusion chemotherapy (HAIC-FOLFOX) for hepatocellular carcinoma with major portal vein invasion.

Article Title:
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study.

Article References:
Yi, J., Wang, J., Zhang, Y. et al. Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73131-y

Image Credits: AI Generated